Chang 1979a.

Study characteristics
Methods	Randomised, double‐blind, 3‐period cross‐over, placebo‐controlled trial
Participants	15 people (10/15 (67%) men/5/15 (33%) women) aged 15‐49 years (median = 24 years). 4/15 (27%) participants were cannabis naive Tumour type: osteogenic sarcoma Chemotherapy regimens: methotrexate 250 mg/kg with leucovorin calcium rescue every 3 weeks for 18 months Chemotherapy emetogenicity: low
Interventions	Dronabinol 10 mg/m2 orally every 3 hours for total 5 doses (Phase I), n = 15. If participant vomited during this period oral dose was replaced with THC cigarette for remaining doses Placebo, n = 15
Outcomes	Episodes of nausea and vomiting on day of therapy; frequency and severity of nausea; episodes of sedation, euphoria, dizziness, depression, paranoia
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Order of THC‐placebo administration was randomized into three paired trials"
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	58/77 (75%) participants received THC, 39/53 (74%) participants received placebo
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Low risk	Groups balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Identical gelatin capsules with sesame oil". "Identical cigarettes, the odour and taste of a lit placebo cigarette were identical to those of cannabis cigarette"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double‐blind"